Neuromuscular disease (including some myelopathies) Flashcards
Metabolic myopathies
Most metabolic myopathies present as exercise intolerance (dynamic dysfunction).
Acid maltase deficiency (Type 2: Pompe) and Debranching enzyme deficiency (Type 3: Cori) are important exceptions presenting as myopathies with respiratory involvement (static dysfunction).
Axonal neuropathy
There is an overall loss of axons
– The cleared spaces (arrow) are where axons used to traverse.
– There are small groups of thinly myelinated axons indicating early phases of reinnervation (circle).
Demyelinating neuropathy
“Onion bulbing” due to chronic demyelination and remyelination
Seen in CMT, CIDP, HNPP
Tomaculae
Sausage-shaped focal swellings in the myelin sheath
Seen in HNPP
Target or targetoid fibers
Neuropathic muscle biopsy
Target or targetoid fibers, that are best observed with NADH-TR staining (for assessing oxidative enzymatic function in the muscle). Target fibers are characterized by the presence of three zones, each with varying stain intensity, within the cell. The pale central zone results from reduced oxidative enzymatic activity, disorganized myofibrils, and a paucity of mitochondria. The central zone is encircled by a darkly stained zone, that is enriched with mitochondria and has increased enzymatic activity. The third zone stains normally, and is at the periphery of the myofiber. T_arget fibers are most commonly type I muscle fibers (slow fibers)_
.
Angular fibers
Neuropathic muscle biopsy
The earliest structural change in neurogenic atrophy seen on muscle biopsy is the loss of the polygonal shape of the muscle fiber.(18) A pattern of scattered, atrophic muscle fibers involving both types I and II fibers is another early finding. The atrophic fibers become small and angulated.
Fiber type grouping
Neuropathic muscle biopsy
Clustering of type 1 or type 2 fibers
Occurs with re-innervation - if re-innervation occurs, fiber-type grouping will be evident with ATPase staining and the normal patchwork pattern will no longer be evident. Instead, groups of similar fiber-types will lie adjacent to one another. This phenomenon occurs after denervation followed by reinnervation, when a single remaining near-by motor neuron sprouts and re-innervates multiple atrophied muscle fibers, altering the fiber-type to reflect the metabolic signature of the re-innervating motor neuron.
Group atrophy
Neuropathic muscle biopsy
Refers to atrophy of groups of muscle fibers in which muscle fibers belonging to the same motor unit are simultaneously affected. The number of fibers affected within a group varies greatly (from less than ten to hundreds)
Inflammatory myopathies
Polymyositis
Inflammation between muscle fibers (endomysial) (circle). with muscle fiber invasion by lymphocytes (arrow).
Inflammatory myopathies
Dermatomyositis
Atrophy of muscle fibers around a fascicle (perifascicular) secondary to capillary inflammation (arrows).
Inflammatory myopathies
Inclusion body myositis
Characterized by serpentine vacuoles studded by amyloid protein inclusions (rimmed vacuoles) (circle).
May also see mild endomysial inflammation
Mitochondrial myopathy
– Subsarcolemmal accumulations of precipitated eosinophilic mitochondria (“ragged red fibers”) (circle).
– On enzymatic staining for cyclooxygenase, which is an essential enzyme in mitochondria oxidative phosphorylation, there are muscle fibers that lack this enzyme (arrow).
Muscular dystrophies - common features
Degenerating fibers/ regenerating fibers (necessary)
Fiber rounding, central nuclei, variation in fiber size (nonspecific)
Increased connective tissue (arrow) and fat (nonspecific).
Diagnosis based on enzyme testing or genetic testings
In Duchenne’s muscular dystrophy, there is severely reduced or absent staining for dystrophin in the muscle membrane (bottom).
Congenital myopathies
Nemaline rod myopathy - purple aggregates of muscle filament originating from the Z-lines
Congenital myopthy
Central core myopathy
Central clearing that runs the entire length of the muscle fiber
ALS
UMN+LMN signs in the absence of sensory symptoms or sensory abnormalities on examination.
A neurodegenerative disorder that affects motor neurons in the anterior horn of the spinal cord, but also the motor cortex and brainstem. Sporadic ALS affects men more than women. It can present at any age but with a peak incidence in the sixth to seventh decade of life.
MC progression - most often muscle weakness begins focally, usually in the extremities (two-thirds of cases) and spreads to involve contiguous regions.
The split-hand phenomenon is a feature of ALS, characterized by weakness and atrophy of the lateral hand (thenar and first dorsal interosseous muscles) with relative sparing of the medial hand (hypothenar) muscles.
Approximately one-third of patients present with bulbar symptoms, such as dysarthria or dysphagia (bulbar-onset ALS).
Pseudobulbar palsy can occur in ALS. Cognitive impairment of some degree is present in up to 50% of patients with ALS; it is mostly subclinical, but can be detected on neuropsychological testing. In a small protein of cases, cognitive dysfunction can manifest as dementia - typically FTD - and occurs most frequent in patients with bulbar-onset ALS.
The region of motor neurons in the sacral spinal cord that are responsible for sphincter control, Onufrowicz’s nucleus (also known as Onuf’s nucleus) is generally spared in ALS, and sphincter dysfunction is typically not a prominent problem. Sensory nerve involvement and dysautonomia are also uncommon in ALS although they can occur.
Progressive muscular atrophy
_LMN - a diagnosis of PMA is usually reserved for patients who have electrodiagnostic evidence of motor neuron disease and have isolated lower motor neuron findings at least 3 years from symptom onse_t.
It often presents with focal asymmetric distal weakness that later involves more proximal regions and other extremities, with lower motor neuron features on examination such as atrophy, hyporeflexia, and fasciculations. PMA begins at an earlier age as compared to ALS, and survival is often longer than ALS, with a median survival of 5 years though more rapidly progressive and more chronic forms of the disease occur.
Bulbar and respiratory symptoms occur later than in ALS
Laboratory evaluation may reveal moderately elevated creatine kinase, but never more than 10 times normal, and EMG shows evidence of motor neuron disease.
PLS - pathology
Autopsy in patients with PLS has shown significant cell loss in layer 5 of the motor and premotor cortex, predominantly the large pyramidal Betz cells with corticospinal tract degeneration.
Primary lateral sclerosis
UMN
Presence of upper motor neuron signs at least 3 years from symptom onset without evidence of lower motor neuron dysfunction. (The majority of ALS patients who present with predominantly upper motor neuron signs and symptoms eventually develop lower motor neuron involvement by 3 to 4 years.)
It typically presents in the sixth decade of life with a progressive spastic tetraparesis and later, cranial nerve involvement. Rarely, bulbar onset occurs. Spasticity, rather than muscle weakness or atrophy, is the most prominent feature. It typically progresses slowly over years. Autonomic involvement does not typically occur.
Treatment of PLS is symptomatic, and usually includes baclofen (a GABAB agonist) or tizanidine (an α2-agonist) to reduce spasticity.
Vs hereditary spastic paraparesis - will see a family hx in HSP and usually white matter changes on MRI brain and C-spine
Progressive bulbar palsy
UMN+LMN of bulbar segment
ALS - genetics
90% sporadic, 10% familial with 20% of familial secondary to mutations SOD1: Cu, Zn dimutase on chsm 21q22 with A4V MC mutation in North America
C9orf72 hexanucleotide expansion identified as the most common cause of genetic ALS (and mutations have also been identified in sporadic disease)
*Mutations also described in TDP-43, FUS, ANG, VCP, FIG4 and other genes
ALS - riluzole
Inhibits glutamate release
ALS and associated s(x)s
15-50% with frontotemporal dementia on exam
– Mutations in C9orf72, TDP-43, VCP and FUS also cause FTLD
ALS pathology
Bunina bodies: eosinophilic cytoplasmic incisions in the anterior horn motor neurons, specific for ALS